GenOway Expands into Japan, the 3rd Largest Preclinical Research Market in the World
GenOway announces the establishment of GenOway Japan, a wholly-owned subsidiary aimed at promoting and developing the sale of preclinical models in immuno-oncology and immuno-inflammation to the Japanese pharmaceutical and biotechnological industry. This initiative is part of the group's international strategy, replicating the model that succeeded in China.
Establishing a New Subsidiary in a Key Market
GenOway has established its first subsidiary in Japan, a market it describes as the third largest global market for preclinical research, following the United States and China. The group already counts major players in the Japanese pharmaceutical sector among its clients, including Takeda, Eisai, and Ono Pharmaceutical. According to the company, the strategy involves replicating the successful model from China by forming a sales team that can provide enhanced proximity and added scientific value to the Japanese market players.
Leadership and Strategic Appointments
The management of GenOway Japan has been entrusted to Dr. Hideki Hanaoka, who has over twenty years of experience in the Japanese life sciences industry, particularly in genomics and cellular technologies. Philippe Fauchet, former President for Sanofi and GSK in Japan and South Korea, chairs the subsidiary's Board of Directors as an independent administrator. GenOway plans to establish a fully autonomous commercial team of five scientists within a year. The first sales are expected by the end of the first half of 2026.
